Equities research analysts forecast that Marinus Pharmaceuticals Inc (NASDAQ:MRNS) will post ($0.20) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Marinus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.14). Marinus Pharmaceuticals posted earnings per share of ($0.24) in the same quarter last year, which suggests a positive year over year growth rate of 16.7%. The company is expected to issue its next earnings results on Monday, March 9th.
According to Zacks, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.94) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.84). For the next year, analysts expect that the firm will report earnings of ($0.65) per share, with EPS estimates ranging from ($1.00) to ($0.50). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Marinus Pharmaceuticals.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02).
A number of equities research analysts recently weighed in on MRNS shares. Oppenheimer started coverage on Marinus Pharmaceuticals in a research note on Thursday, December 19th. They set an “outperform” rating and a $6.00 price objective for the company. HC Wainwright upped their price objective on Marinus Pharmaceuticals from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Zacks Investment Research cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th. LADENBURG THALM/SH SH restated a “buy” rating and set a $5.00 price objective on shares of Marinus Pharmaceuticals in a research note on Monday, November 18th. Finally, ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Marinus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $5.90.
Shares of NASDAQ MRNS traded down $0.03 during mid-day trading on Friday, reaching $2.27. 9,474 shares of the company were exchanged, compared to its average volume of 1,270,998. The stock has a market cap of $125.52 million, a price-to-earnings ratio of -2.54 and a beta of 3.12. Marinus Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $5.40. The firm has a 50-day moving average of $1.85 and a 200 day moving average of $1.79.
In other news, CEO Scott Braunstein acquired 100,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00. Corporate insiders own 5.10% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Marinus Pharmaceuticals by 7.2% in the second quarter. BlackRock Inc. now owns 3,427,739 shares of the biopharmaceutical company’s stock valued at $14,226,000 after purchasing an additional 229,811 shares during the period. Vanguard Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 4.7% in the second quarter. Vanguard Group Inc. now owns 2,587,314 shares of the biopharmaceutical company’s stock worth $10,737,000 after buying an additional 115,294 shares during the last quarter. State Street Corp boosted its stake in shares of Marinus Pharmaceuticals by 4.9% in the third quarter. State Street Corp now owns 931,433 shares of the biopharmaceutical company’s stock worth $1,434,000 after buying an additional 43,425 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Marinus Pharmaceuticals by 1.9% in the second quarter. Northern Trust Corp now owns 548,467 shares of the biopharmaceutical company’s stock worth $2,276,000 after buying an additional 10,204 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Marinus Pharmaceuticals by 1,679.6% in the second quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock worth $780,000 after buying an additional 177,331 shares during the last quarter. 57.99% of the stock is currently owned by institutional investors and hedge funds.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More: Real Estate Investment Trust (REIT) ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.